A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
ENGLEWOOD, CO / November 11, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that management will present a corporate...
Live Conference Call and Webcast at 4:30 PM ET ENGLEWOOD, CO / November 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today...
Company's highest revenue quarter to date is more than 2X its entire fiscal 2019 revenue ENGLEWOOD, CO / October 6, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address...
Live Conference Call and Webcast at 4:30 PM ET ENGLEWOOD, CO / October 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today...
ENGLEWOOD, CO / September 23, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that it will reschedule its fourth quarter...
Live Conference Call and Webcast at 4:30 ET ENGLEWOOD, CO / September 16, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today...
Pinnacle Plans to Scale U.S. Manufacturing Capacity to 25 Million Tests Per Month Cost-Effective 15-Minute Rapid Antigen Test Demonstrates 100% Specificity for COVID-19 Detection When Compared with RT-PCR ENGLEWOOD, CO / September 8, 2020 / Aytu BioScience, Inc....
Aytu BioScience COVID-19 IgG/IgM Rapid Test Distribution Partner Apollo Med Innovations Initiates Nationwide Mobile Testing Partnership with Olympus Health and Performance ENGLEWOOD, CO / August 19, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty...
Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 Patients ENGLEWOOD, CO / August 17, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical...
Aytu BioScience's Sublicensee SUDA Pharmaceuticals Secures TGA Approval, Enabling Near-Term Commercialization of ZolpiMist ENGLEWOOD, CO / July 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on...
Article Reports Results from Independent Study Demonstrating Test's 100% Sensitivity and Specificity for IgM Antibodies and 96.7% and 97.5% Sensitivity and Specificity, Respectively, for IgG Antibodies ENGLEWOOD, CO / July 27, 2020 / Aytu BioScience, Inc....
Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States ENGLEWOOD, CO / July 20, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on...
Apollo Med Innovations Introduces Novel Research-Based Testing Approach to Offer COVID-19 Antibody Testing to Nationwide Network of Over 1,000 Medical Clinics and Recently Launched Mobile Testing Platform ENGLEWOOD, CO / July 10, 2020 / Aytu BioScience, Inc....
National Cancer Institute's (NCI) analysis of COVID-19 IgG/IgM Rapid Test Cassette Reported 100% Combined Sensitivity, and 97.5% Combined Specificity for the Lateral Flow Immunoassay ENGLEWOOD, CO / June 9, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty...
ENGLEWOOD, CO / June 8, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant medical needs, is set to join the Russell 3000® Index at the conclusion of the...
Natesto now covered as a Preferred Brand by leading national pharmacy benefits manager ENGLEWOOD, CO / June 3, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address...
Company Retires $15M Obligation Assumed with Previously Announced Cerecor Commercial Portfolio Asset Purchase Company's Debt Reduced to Approximately $1 Million ENGLEWOOD, CO / June 1, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the...
Fourth FDA Emergency Use Authorization of a COVID-19 IgG/IgM Lateral Flow Rapid Test 1.4 Million Rapid Tests Available for Distribution at Company's Warehouse ENGLEWOOD, CO / June 1, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the...
Company Reports Revenue for the Three Months Ended March 31, 2020 of $8.2M, Up 243% Year-over-Year $62.5 Million in Cash and Cash Equivalents as of March 31, 2020 Management to Host Conference Call at 4:30 PM ET ENGLEWOOD, CO / May 14, 2020 / Aytu BioScience, Inc....
ENGLEWOOD, CO / May 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational...
500,000 Rapid Tests Cleared for Shipment to Company's Warehouse ENGLEWOOD, CO / April 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs...
Company has Partnered with Sterling Medical to Finalize the Development of Cedars-Sinai-Developed 'Healight' Medical Device for Use in Patients with Coronavirus ENGLEWOOD, CO / April 27, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty...
Company's Board of Directors Elects Not to Effect a Reverse Stock Split ENGLEWOOD, CO / April 24, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient...
ENGLEWOOD, CO / April 23, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced the signing of a definitive agreement (the "Agreement")...
Nasally-Administered Natesto Testosterone Replacement Therapy Increases Serum Testosterone, Improves Hypogonadal Symptoms While Simultaneously Preserving Semen Parameters and Gonadotropin Hormones ENGLEWOOD, CO / April 21, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU)...
Cedars-Sinai-Developed ‘Healight' Medical Device Platform Technology Being Studied as a Potential First-in-Class COVID-19 Treatment Conference Call Scheduled for Tuesday, April 21, 2020 at 4:30 pm ET ENGLEWOOD, CO / April 20, 2020 / Aytu BioScience, Inc....
Chinese Officials Confirm China Won't Restrict Exports of Medical Products Needed to Fight Coronavirus Company in Late-Stage Negotiations to Secure Distribution Agreement for Additional COVID-19 IgG/IgM Rapid Test Which is Approved by China's National Medical Products...
Independent clinical study demonstrates test accuracy of 98.0% and 94.1% for IgG and IgM, respectively, when using PCR-positive cases as true positives ENGLEWOOD, CO / April 16, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), (the "Company"), a specialty pharmaceutical...
Company Places Third Purchase Order for One Million Tests ENGLEWOOD, CO / April 15, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs today provided an update...
ENGLEWOOD, CO / April 13, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today the launch of Regoxidine®, an over-the-counter foam...
ENGLEWOOD, CO / April 9, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced that, due to Colorado's "shelter in place" order related...
Aytu BioScience Licensee SUDA Pharmaceuticals Expands ZolpiMist Global Footprint Through Exclusive Licensing Agreement with Mitsubishi Tanabe Pharma Corporation ENGLEWOOD, CO / April 8, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty...
Cash and Cash Equivalents of Approximately $62.5 on March 31, 2020 ENGLEWOOD, CO / April 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs...
100,000 COVID-19 Rapid Tests Ready to Ship Across the Country with 500,000 More on the Way ENGLEWOOD, CO / April 6, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address...
First COVID-19 Rapid Tests Delivered to Denver First Responders ENGLEWOOD, CO / April 3, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs...
Initial Shipment of 2-10 Minute COVID-19 Rapid Tests Received at Company's Englewood, Colorado Facility ENGLEWOOD, CO / April 1, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU),(the "Company"), a specialty pharmaceutical company focused on commercializing novel products...
ENGLEWOOD, CO / March 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that its annual meeting of stockholders...
ENGLEWOOD, CO / March 25, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that it received notice from The Nasdaq Stock Market,...
Commercial Distribution of First 100,000 Tests to Commence Upon Receipt of Inbound Product Shipment ENGLEWOOD, CO / March 23, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address...
ENGLEWOOD, CO / March 19, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several...
Company Expects to Seek Regulatory Clearance Under Health Canada and COFEPRIS Expedited Clearance Procedures ENGLEWOOD, CO / March 19, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address...
Updated FDA Policy Likely Enables Near-Term Availability of COVID-19 Test in the U.S. ENGLEWOOD, CO / March 17, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient...
ENGLEWOOD, CO / March 16, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today it was featured on a FOX segment titled: "Englewood company says...
Healthcare professionals, institutions, and other interested parties with questions about the Company's recently licensed COVID-19 IgG/IgM Rapid Test are asked to send email inquiries to COVID-19@aytubio.com ENGLEWOOD, CO / March 13, 2020 / Aytu BioScience, Inc....
ENGLEWOOD, CO / March 12, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several...
ENGLEWOOD, CO / March 11, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single...
Company Expects to Pursue Commercial Use Under FDA's Emergency Use Authorization ENGLEWOOD, CO / March 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs...
Aytu BioScience Enters Consumer Healthcare Market with a Portfolio of Over 35 Products that Generated $24M in Revenue During Past Four Quarters Combination Creates Specialty Rx and Consumer Pharma Company with LTM Revenue of Approximately $43M ENGLEWOOD, CO & SAN...
ENGLEWOOD, CO / February 13, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant medical needs, today will provide an overview of its business, including the company's...
ENGLEWOOD, CO / February 6, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that the company will present its operational results for the...